RE-BVS – Piemonte Repository

Sfoglia per AUTORE
AMATU A
Collezione AOU Città della Salute di Torino

Items : 8

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. in ESMO open / ESMO Open. 2021 Oct;6(5):100246. doi: 10.1016/j.esmoop.2021.100246. Epub 2021 Aug 17.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Di Bartolomeo M; Pietrantonio F; Di Maio M; Morano F; Corallo S; Berenato R; Ratti M; Clavarezza M; Zaniboni A; Murialdo R; Tampellini M; Ritorto G; Raimondi A; Fucà G; Leone AG; Lonardi S; Antoniotti C; Smiroldo V; Amatu A;

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3.

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

de Braud F; Di Bartolomeo M; Pietrantonio F; Randon G; Prisciandaro M; Ambrosini M; Pagani F; Niger M; Antista M; Longarini R; Cinieri S; Giordano M; Antonuzzo L; Petrelli F; Toscano G; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Racca P; Amatu A; Rimassa L; Antoniotti C; Morano F; Lonardi S; Corallo S; Raimondi A;

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. in The oncologist / Oncologist. 2019 Oct;24(10):1395-1402. doi: 10.1634/theoncologist.2018-0785. Epub 2019 Apr 5.

2019
AOU Città della Salute di Torino

Bardelli A; Zagonel V; Marrapese G; Ciardiello F; Vaghi C; Martino C; Bonoldi E; Valtorta E; Racca P; Tosi F; Borelli B; Martinelli E; Bergamo F; Fenocchio E; Leone F; Lonardi S; Ghezzi S; Amatu A; Porcu L; Sartore-Bianchi A; Trusolino L; Torri V; Marsoni S; Siena S;

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. in Gut / Gut. 2018 Nov;67(11):1995-2005. doi: 10.1136/gutjnl-2016-313372. Epub 2017 Oct 5.

2018
AOU Città della Salute di Torino

Di Nicolantonio F; Sartore-Bianchi A; Bardelli A; Esteller M; Siena S; Michels KB; Racca P; Grady WM; Truini M; Matullo G; Zavattari P; Vanzati A; Maden S; Bencardino K; Bustreo S; Cancelliere C; Guarrera S; Cristiano C; Oddo D; Binder AM; Falcomatà C; Mussolin B; Cassingena A; Ponzetti A; Moran S; Siravegna G; Barault L; Amatu A;

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.

2016
AOU Città della Salute di Torino

Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; et alii...

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). in Cancer / Cancer. 2016 Feb 15;122(4):574-81. doi: 10.1002/cncr.29778. Epub 2015 Nov 5.

2016
AOU Città della Salute di Torino

Siena S; Ciuffreda L; Fasola G; Aprile G; Cagnazzo C; Amatu A; Montano M; Nasti G; Spadi R; Belli C; Filippi R; Cereda S; Marino D; Leone F; Reni M; Aglietta M;

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Sep;26(9):1994-1999. doi: 10.1093/annonc/mdv272. Epub 2015 Jun 25.

2015
AOU Città della Salute di Torino

Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F;

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. in Nature medicine / Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1.

2015
AOU Città della Salute di Torino

Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; et alii...